Abbott said that an ongoing multisite clinical study indicated that its rapid COVID-19 test was accurate when detecting the virus nearly 95% of the time. Abbott said that an ongoing multisite ...

Abbott expects the test to be available in emergency rooms and urgent care centers this summer. A blood test designed to aid in the rapid diagnosis of concussions has gained FDA approval.

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

The rapid tests are produced by Abbott Labs and are called the BinaxNOW COVID-19 Ag Card. There was a prior Abbott rapid test called the ID Now, which had been criticised in some studies for an ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while ...

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.